EQL Pharma Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 3/6
EQL Pharma has a total shareholder equity of SEK188.1M and total debt of SEK140.5M, which brings its debt-to-equity ratio to 74.7%. Its total assets and total liabilities are SEK406.6M and SEK218.5M respectively. EQL Pharma's EBIT is SEK39.9M making its interest coverage ratio 5.9. It has cash and short-term investments of SEK13.4M.
Anahtar bilgiler
74.7%
Borç/özkaynak oranı
SEK 140.45m
Borç
| Faiz karşılama oranı | 5.9x |
| Nakit | SEK 13.37m |
| Eşitlik | SEK 188.13m |
| Toplam yükümlülükler | SEK 218.46m |
| Toplam varlıklar | SEK 406.59m |
Son finansal sağlık güncellemeleri
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden
Aug 12
Is EQL Pharma (NGM:EQL) Using Too Much Debt?
Apr 29Recent updates
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher
Oct 29EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings
Aug 22Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden
Aug 12EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce
Jun 13EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price
May 14EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 21The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested
Jun 28With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case
Apr 28EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors
Feb 24EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital
Dec 19Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?
Jun 29Is EQL Pharma (NGM:EQL) Using Too Much Debt?
Apr 29We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair
Aug 10EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns
Jun 07If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late
Apr 16How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?
Mar 11Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 21Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 03What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation
Jan 16
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?
Dec 28What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?
Dec 11EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment
Nov 22Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: EQL's short term assets (SEK223.9M) exceed its short term liabilities (SEK181.6M).
Uzun Vadeli Yükümlülükler: EQL's short term assets (SEK223.9M) exceed its long term liabilities (SEK36.8M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: EQL's net debt to equity ratio (67.5%) is considered high.
Borcun Azaltılması: EQL's debt to equity ratio has increased from 0% to 74.7% over the past 5 years.
Borç Kapsamı: EQL's operating cash flow is negative, therefore debt is not well covered.
Faiz Kapsamı: EQL's interest payments on its debt are well covered by EBIT (5.9x coverage).